Bulk Inquiry
Foretinib
- GSK 1363089 - Exel 2880 - XL 880
- Soluble in DMSO
- MF: C34H34F2N4O6
- MW: 632.65
Description
Foretinib (XL880) is an orally available multi-kinase inhibitor targeting c-MET and VEGFR2 with reported IC50 value of 0.4 nM for c-MET.
Foretinib combines inhibition of tumor-cell invasive signaling through MET with antiangiogenic VEGFR pathway blockade. It is relevant for studying RTK-driven tumor growth, angiogenesis, metastasis-associated signaling and kinase-inhibitor combination strategies.
Key Features
- Potent c-MET and VEGFR2 inhibitor
- Reported c-MET IC50: 0.4 nM
- Targets tumor invasion and angiogenic signaling pathways
- Useful for multi-target RTK pharmacology research
Applications
- MET and VEGFR kinase assays
- Angiogenesis and tumor vascularization research
- Cancer invasion and metastasis models
- Receptor tyrosine kinase inhibitor profiling
More Information
| Parent CAS No. | 849217-64-7 |
|---|---|
| Chemical Name | N-(4-(7-(3-morpholinopropoxy)-6-methoxyquinolin-4-yloxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| SMILES | C1(OC)C=C2C(OC3C(F)=CC(NC(C4(CC4)C(=O)NC4C=CC(F)=CC=4)=O)=CC=3)=CC=NC2=CC=1OCCCN1CCOCC1 |
| MFCD | MFCD16038048 |
| InChi | InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42) |
| InChiKey | CXQHYVUVSFXTMY-UHFFFAOYSA-N |
| CID | 42642645 |
| Short Description | MET/VEGFR2 inhibitor |
References
- JP Eder et al. A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2. Clin. Cancer Res. 2010, 16(13), 3507.
- L Liu et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009, 69(17), 6871-8.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1394 | Imatinib mesylate |
From $66.00 |
| 1398 | Sunitinib malate |
From $88.00 |
| 1414 | AG 013736 |
From $55.00 |
| 1415 | CT 53518 |
From $77.00 |
| 1419 | AB 1010 |
From $77.00 |
| 1420 | Pazopanib hydrochloride |
From $66.00 |
| 1547 | OSI 930 |
From $99.00 |
| 1581 | SU 11274 |
From $99.00 |
| 1583 | PF 04217903 mesylate |
From $88.00 |
| 1638 | ABT 869 |
From $88.00 |
| 1660 | Crizotinib |
From $88.00 |
| 1678 | Regorafenib |
From $77.00 |
| 1696 | Quizartinib dihydrochloride |
From $99.00 |
| 1768 | AMG 706 |
From $115.50 |
| 1819 | Cabozantinib S-malate |
From $66.00 |
| 1838 | ARQ 197 |
From $99.00 |
| 1891 | SU 6668 |
From $110.00 |
| 1914 | SGX 523 |
From $132.00 |
| 1916 | AMG 208 |
From $104.50 |
| 1959 | Golvatinib |
From $99.00 |
| 2368 | Amuvatinib |
From $132.00 |
| 2501 | Pexidartinib |
From $66.00 |
| 2553 | LY 2801653 |
From $132.00 |
| 2767 | SU11652 |
From $154.00 |
